SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ELAN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
March 31, 2026 381.00M
December 31, 2025 338.00M
September 30, 2025 351.00M
June 30, 2025 400.00M
March 31, 2025 341.00M
December 31, 2024 300.00M
September 30, 2024 323.00M
June 30, 2024 354.00M
March 31, 2024 337.00M
December 31, 2023 292.00M
September 30, 2023 313.00M
June 30, 2023 353.00M
March 31, 2023 327.00M
December 31, 2022 303.00M
September 30, 2022 298.00M
June 30, 2022 343.00M
March 31, 2022 323.00M
Date Value
December 31, 2021 327.00M
September 30, 2021 342.00M
June 30, 2021 385.00M
March 31, 2021 348.00M
December 31, 2020 374.10M
September 30, 2020 277.70M
June 30, 2020 162.80M
March 31, 2020 182.00M
December 31, 2019 185.90M
September 30, 2019 192.30M
June 30, 2019 200.90M
March 31, 2019 181.10M
December 31, 2018 185.10M
September 30, 2018 179.00M
June 30, 2018 191.10M
March 31, 2018 180.00M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Zoetis, Inc. 588.00M
Eli Lilly & Co. 2.934B
Phibro Animal Health Corp. 81.02M
Royalty Pharma Plc 159.49M
ANI Pharmaceuticals, Inc. 73.66M